Intravenous cefuroxime as a first-line treatment for women hospitalized for pyelonephritis.


Journal

JAC-antimicrobial resistance
ISSN: 2632-1823
Titre abrégé: JAC Antimicrob Resist
Pays: England
ID NLM: 101765283

Informations de publication

Date de publication:
Jun 2024
Historique:
received: 29 01 2024
accepted: 15 04 2024
medline: 8 5 2024
pubmed: 8 5 2024
entrez: 8 5 2024
Statut: epublish

Résumé

Empirical treatment of pyelonephritis in the emergency ward includes broad-spectrum antibiotics. Such a strategy favours broad-spectrum antibiotic overuse. Local antibiotic stewardship teams can propose local recommendations to adapt empirical antibiotic treatment devoted to spare precious molecules that remain active on MDR bacteria, such as fluoroquinolones or other broad-spectrum antibiotics. We aimed to evaluate the incidence of urinary tract infection recurrence within 3 months after hospital discharge following empirical antibiotic therapy with cefuroxime in women with pyelonephritis in the emergency room. We conducted a retrospective, single-centre study. We identified 109 women treated for pyelonephritis, 95 with cefuroxime at any time, and 14 with only other antibiotics, and divided them into subgroups based on antibiotic switch to other molecules. We compared the incidence of urinary tract infection recurrence in the subgroups. In the group of patients treated with cefuroxime only, we identified five cases of recurrence (9.4%) in a total of 53 patients, but only 1 (1.9%) case of recurrence associated with the same uropathogen. No significant difference in clinical outcome, length of antibiotic treatment, or urinary tract infection recurrence was observed between the subgroups. Our study supports that a strategy elaborated by an antibiotic stewardship team based on local ecology and aimed at proposing the narrowest-spectrum antibiotic upon treatment initiation in the emergency room is safe.

Sections du résumé

Background UNASSIGNED
Empirical treatment of pyelonephritis in the emergency ward includes broad-spectrum antibiotics. Such a strategy favours broad-spectrum antibiotic overuse. Local antibiotic stewardship teams can propose local recommendations to adapt empirical antibiotic treatment devoted to spare precious molecules that remain active on MDR bacteria, such as fluoroquinolones or other broad-spectrum antibiotics.
Objectives UNASSIGNED
We aimed to evaluate the incidence of urinary tract infection recurrence within 3 months after hospital discharge following empirical antibiotic therapy with cefuroxime in women with pyelonephritis in the emergency room.
Patients and methods UNASSIGNED
We conducted a retrospective, single-centre study. We identified 109 women treated for pyelonephritis, 95 with cefuroxime at any time, and 14 with only other antibiotics, and divided them into subgroups based on antibiotic switch to other molecules. We compared the incidence of urinary tract infection recurrence in the subgroups.
Results UNASSIGNED
In the group of patients treated with cefuroxime only, we identified five cases of recurrence (9.4%) in a total of 53 patients, but only 1 (1.9%) case of recurrence associated with the same uropathogen. No significant difference in clinical outcome, length of antibiotic treatment, or urinary tract infection recurrence was observed between the subgroups.
Conclusions UNASSIGNED
Our study supports that a strategy elaborated by an antibiotic stewardship team based on local ecology and aimed at proposing the narrowest-spectrum antibiotic upon treatment initiation in the emergency room is safe.

Identifiants

pubmed: 38716400
doi: 10.1093/jacamr/dlae071
pii: dlae071
pmc: PMC11073747
doi:

Types de publication

Journal Article

Langues

eng

Pagination

dlae071

Informations de copyright

© The Author(s) 2024. Published by Oxford University Press on behalf of British Society for Antimicrobial Chemotherapy.

Auteurs

Céline Everard (C)

Service of Internal Medicine, Clinique Saint-Pierre, Ottignies, Belgium.

Axelle Schampaert (A)

Service of Internal Medicine, Clinique Saint-Pierre, Ottignies, Belgium.

Louise Doyen (L)

Service of Internal Medicine, Clinique Saint-Pierre, Ottignies, Belgium.

Valérie Verbelen (V)

Service of Microbiology, Clinique Saint Pierre, Ottignies, Belgium.

Jean-Christophe Marot (JC)

Service of Internal Medicine, Clinique Saint-Pierre, Ottignies, Belgium.

Grégoire Wieërs (G)

Service of Internal Medicine, Clinique Saint-Pierre, Ottignies, Belgium.
Faculty of Medicine, Department of Medicine, URPC, Namur Research Institute for Life Sciences (NARILIS), University of Namur, Namur, Belgium.

Classifications MeSH